Authors Posts by BiotechBlog



Financing On Target For A Stellar Year
It’s beginning to look a lot like 2001 – or better. In the first nine months of 2003, biotech companies raised nearly $11.8 billion in new funds (excluding revenues and payments from corporate partners), putting the sector on track for at least equaling – if not topping -the $14.7 billion raised in 2001. We’ve already beat 2002’s total of $10.9 billion for the year and chances are excellent that 2003 will turn out to be the second-best fund-raising year ever.

Affymetrix sells new gene chip / Chip represents full human genome
Affymetrix Inc. of Santa Clara won the race Thursday to market a single gene chip packed with fragments from each of the 35,000 known genes that make up the human genome.
But two other Bay area companies, Agilent Technologies of Palo Alto and Applied Biosystems of Foster City, are close behind with their own versions of a whole-genome microarray, or chip.
The chips mark a major technical advance in the use of human genetic information to find new drugs, and eventually, to tailor treatments based on differences in each patient’s DNA.

FDA’s McClellan Calls for More Sharing of Drug R&D Costs
The U.S. is bearing a disproportionate share of drug research and development costs for medicines used globally, FDA commissioner Mark McClellan said Thursday.

He called for more equitable cost sharing and price setting. ‘If we do not find better ways to share the burden of developing new drugs and biologics, all of us will suffer’

“Small drug discovery firms are capitalizing on the positive momentum that’s returned to the market for biotechnology stocks. A dozen have announced plans this quarter to launch initial public stock offerings (IPOs), while nearly as many more hope to raise money through follow-on bids. The upturn, if it persists, may help rescue a sector where limited cash flow has precipitated major cutbacks and consolidation.”